SARS-CoV-2 (COVID-19) NSP8 Protein, His Tag

ユーザーレビュー
製品番号/仕様
価格
数量
NS8-C5149-100ug
$410.00
NS8-C5149-1mg
$2945.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    NSP8, nsp8, Non-structural protein 8

  • Source

    SARS-CoV-2 NSP8, His Tag (NS8-C5149) is expressed from E. coli cells. It contains AA Ala 1 - Gln 198 (Accession # YP_009725304.1).

    Predicted N-terminus: Met

    Request for sequence
  • Molecular Characterization

    NSP8 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 23.9 kDa. The protein migrates as 22-25 kDa under reducing (R) condition (SDS-PAGE).

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in 20 mM Tris, 250 mM NaCl, pH8.5 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    NSP8 SDS-PAGE

    SARS-CoV-2 NSP8, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

ユーザーレビュー
コメントを投稿

バックグランド

NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    SARS-CoV-2-3C-like-proteinase

  • カテゴリ:

  • 市販の医薬品数:

    6 詳細

  • 治験医薬品数:

    28 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8